Ⅱ型神经纤维瘤病相关听神经瘤治疗进展

doi:10.3969/j.issn.1672-6731.2022.12.003

摘要/Abstract

摘要： Ⅱ型神经纤维瘤病（NF2）是常染色体显性遗传性疾病，病死率和病残率较高，双侧听神经瘤在其诊断与治疗中具有重要意义，平衡治疗方法与患者生活质量是NF2相关听神经瘤治疗的关键。本文综述NF2相关听神经瘤的治疗前监测、治疗方法和听力重建进展，以为临床诊断与治疗提供参考。

关键词: 神经纤维瘤病2型, 神经瘤,听, 综述

Abstract: Neurofibromatosis type 2 (NF2) is an autosomal dominant inherited diseases. NF2 patients suffer a high mortality and disability rate. Bilateral vestibular schwannoma play an important role in its diagnosis and treatment. The balance of treatment and life quality is the key factor in the treatment of NF2-associated vestibular schwannoma. This review summarized the recent advance of monitoring before treatment, treatment strategies and hearing reconstruction in NF2-associated vestibular schwannoma, in order to provide reference for clinical diagnosis and treatment.

Key words: Neurofibromatosis 2, Neuroma, acoustic, Review

杨智君, 刘丕楠. Ⅱ型神经纤维瘤病相关听神经瘤治疗进展[J]. 中国现代神经疾病杂志, 2022, 22(12): 1017-1020.

YANG Zhi-jun, LIU Pi-nan. Recent advance on the treatment of neurofibromatosis type 2-associated vestibular schwannoma[J]. Chinese Journal of Contemporary Neurology and Neurosurgery, 2022, 22(12): 1017-1020.

http://journal11.magtechjournal.com/cjcnn/CN/Y2022/V22/I12/1017

参考文献

[1] Filizoglu N, Ozguven S. Neurofibromatosis type 2:multiple meningiomatosis and vestibular schwannomas on 68 Ga-DOTATATE PET/CT[J]. Clin Nucl Med, 2022, 47:e710-712.
[2] Ren Y, Chari DA, Vasilijic S, Welling DB, Stankovic KM. New developments in neurofibromatosis type 2 and vestibular schwannoma[J]. Neurooncol Adv, 2020, 3:vdaa153.
[3] Tamura R. Current understanding of neurofibromatosis type 1, 2, and schwannomatosis[J]. Int J Mol Sci, 2021, 22:5850.
[4] Bachir S, Shah S, Shapiro S, Koehler A, Mahammedi A, Samy RN, Zuccarello M, Schorry E, Sengupta S. Neurofibromatosis type 2(NF2) and the implications for vestibular schwannoma and meningioma pathogenesis[J]. Int J Mol Sci, 2021, 22:690.
[5] Wang VY, Liu TY, Fang TY, Chen YH, Huang CJ, Wang PC. Clinical manifestations and genetic analysis of a family with neurofibromatosis type 2[J]. Acta Otolaryngol, 2022, 142:36-42.
[6] Coy S, Rashid R, Stemmer-Rachamimov A, Santagata S. An update on the CNS manifestations of neurofibromatosis type 2[J]. Acta Neuropathol, 2020, 139:643-665.
[7] Gugel I, Grimm F, Teuber C, Kluwe L, Mautner VF, Tatagiba M, Schuhmann MU. Management of NF2-associated vestibular schwannomas in children and young adults:influence of surgery and clinical factors on tumor volume and growth rate[J]. J Neurosurg Pediatr, 2019.[Epub ahead of print]
[8] Rajendran S, Antonios J, Solomon B, Kim HJ, Wu T, Smirniotopoulos J, Scott G, Benzo S, Hayes C, Heiss JD, Chittiboina P. A prospective evaluation of swallowing and speech in patients with neurofibromatosis type 2[J]. J Neurol Surg B Skull Base, 2021, 82:244-250.
[9] Helbing DL, Schulz A, Morrison H. Pathomechanisms in schwannoma development and progression[J]. Oncogene, 2020, 39:5421-5429.
[10] Yao L, Alahmari M, Temel Y, Hovinga K. Therapy of sporadic and NF2-related vestibular schwannoma[J]. Cancers (Basel), 2020, 12:835.
[11] Li SW, Zhang J, Tang HL, Li P, Wang B, Zhao F, Liu PN. Establishment of nomograms for the prediction of useful hearing loss in patients with neurofibromatosis type 2[J]. J Neurooncol, 2021, 155:373-381.
[12] Gugel I, Zipfel J, Hartjen P, Kluwe L, Tatagiba M, Mautner VF, Schuhmann MU. Managing NF2-associated vestibular schwannomas in children and young adults:review of an institutional series regarding effects of surgery and bevacizumab on growth rates, tumor volume, and hearing quality[J]. Childs Nerv Syst, 2020, 36:2471-2480.
[13] Lerner DK, Lee D, Naples JG, Brant JA, Bigelow D, Alonso-Basanta M, Ruckenstein MJ. Factors associated with facial nerve paresis following Gamma Knife for vestibular schwannoma[J]. Otol Neurotol, 2020, 41:e83-88.
[14] Jia H, Nguyen Y, Hochet B, Smail M, Mosnier I, Wu H, Sterkers O, Kalamarides M, Bernardeschi D. NF2-related intravestibular schwannomas:long-term outcomes of cochlear implantation[J]. Otol Neurotol, 2020, 41:94-99.
[15] Morselli C, Boari N, Artico M, Bailo M, Piccioni LO, Giallini I, de Vincentiis M, Mortini P, Mancini P. The emerging role of hearing loss rehabilitation in patients with vestibular schwannoma treated with Gamma Knife radiosurgery:literature review[J]. Neurosurg Rev, 2021, 44:223-238.
[16] Kim J, Byeon Y, Song SW, Cho YH, Hong CK, Hong SH, Kim JH, Lee DH, Park JE, Kim HS, Kim YH. Vestibular schwannoma associated with neurofibromatosis type 2:clinical course following stereotactic radiosurgery[J]. Front Oncol, 2022, 12:996186.
[17] Tosi U, Maayan O, An A, Lavieri MET, Guadix SW, DeRosa AP, Christos PJ, Pannullo S, Stieg PE, Brandmaier A, Knisely JPS, Ramakrishna R. Stereotactic radiosurgery for vestibular schwannomas in neurofibromatosis type 2 patients:a systematic review and meta-analysis[J]. J Neurooncol, 2022, 156:431-441.
[18] Whitmeyer M, Brahimaj BC, Beer-Furlan A, Alvi S, Epsten MJ, Crawford F, Byrne RW, Wiet RM. Resection of vestibular schwannomas after stereotactic radiosurgery:a systematic review[J]. J Neurosurg, 2020.[Epub ahead of print]
[19] Chung LK, Nguyen TP, Sheppard JP, Lagman C, Tenn S, Lee P, Kaprealian T, Chin R, Gopen Q, Yang I. A systematic review of radiosurgery versus surgery for neurofibromatosis type 2 vestibular schwannomas[J]. World Neurosurg, 2018, 109:47-58.
[20] Kruyt IJ, Verheul JB, Hanssens PEJ, Kunst HPM. Gamma Knife radiosurgery for treatment of growing vestibular schwannomas in patients with neurofibromatosis type 2:a matched cohort study with sporadic vestibular schwannomas[J]. J Neurosurg, 2018, 128:49-59.
[21] Plotkin SR, Stemmer-Rachamimov AO, Barker FG 2nd, Halpin C, Padera TP, Tyrrell A, Sorensen AG, Jain RK, di Tomaso E. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2[J]. N Engl J Med, 2009, 361:358-367.
[22] Lu VM, Ravindran K, Graffeo CS, Perry A, Van Gompel JJ, Daniels DJ, Link MJ. Efficacy and safety of bevacizumab for vestibular schwannoma in neurofibromatosis type 2:a systematic review and meta-analysis of treatment outcomes[J]. J Neurooncol, 2019, 144:239-248.
[23] Goutagny S, Kalamarides M. Medical treatment in neurofibromatosis type 2:review of the literature and presentation of clinical reports[J]. Neurochirurgie, 2018, 64:370-374.
[24] Sanchez LD, Bui A, Klesse LJ. Targeted therapies for the neurofibromatoses[J]. Cancers (Basel), 2021, 13:6032.
[25] Eitutis ST, Jansen T, Borsetto D, Scoffings DJ, Tam YC, Panova T, Tysome JR, Donnelly NP, Axon PR, Bance ML. Cochlear Implantation in NF2 patients without intracochlear schwannoma removal[J]. Otol Neurotol, 2021, 42:1014-1021.
[26] Tadokoro K, Bartindale MR, El-Kouri N, Moore D, Britt C, Kircher M. Cochlear implantation in vestibular schwannoma:a systematic literature review[J]. J Neurol Surg B Skull Base, 2021, 82:643-651.
[27] Tian L, West N, Cayé-Thomasen P. Cochlear implantation after radiotherapy of vestibular schwannomas[J]. J Int Adv Otol, 2021, 17:452-460.
[28] Patel NS, Carlson ML, Link MJ, Neff BA, Van Gompel JJ, Driscoll CLW. Cochlear implantation after radiosurgery for vestibular schwannoma[J]. J Neurosurg, 2021, 135:126-135.
[29] Deep NL, Patel EJ, Shapiro WH, Waltzman SB, Jethanamest D, McMenomey SO, Roland JT Jr, Friedmann DR. Cochlear implant outcomes in neurofibromatosis type 2:implications for management[J]. Otol Neurotol, 2021, 42:540-548.
[30] Wick CC, Butler MJ, Yeager LH, Kallogjeri D, Durakovic N, McJunkin JL, Shew MA, Herzog JA, Buchman CA. Cochlear implant outcomes following vestibular schwannoma resection:systematic review[J]. Otol Neurotol, 2020, 41:1190-1197.
[31] Egra-Dagan D, van Beurden I, Barber SR, Carter CL, Cunnane ME, Brown MC, Herrmann BS, Lee DJ. Adult auditory brainstem implant outcomes and three-dimensional electrode array position on computed tomography[J]. Ear Hear, 2021, 42:1741-1754.
[32] Wang DX, Wang S, Jian MY, Han RQ. Awake craniotomy for auditory brainstem implant in patients with neurofibromatosis type 2:four case reports[J]. World J Clin Cases, 2021, 9:7512-7519.
[33] Dhanasingh A, Hochmair I. ABI-auditory brainstem implant[J]. Acta Otolaryngol, 2021, 141:63-81.
[34] Sanna M, Di Lella F, Guida M, Merkus P. Auditory brainstem implants in NF2 patients:results and review of the literature[J]. Otol Neurotol, 2012, 33:154-164.
[35] Maini S, Cohen MA, Hollow R, Briggs R. Update on long-term results with auditory brainstem implants in NF2 patients[J]. Cochlear Implants Int, 2009, 10 Suppl 1:33-37.
[36] Noonan KY, Rock J, Barnard Z, Lekovic GP, Brackmann DE, Wilkinson EP. Bilateral auditory brainstem implants in patients with neurofibromatosis 2[J]. Otolaryngol Head Neck Surg, 2021, 165:339-343.

选择文件类型/文献管理软件名称

选择包含的内容

2 Ⅱ型神经纤维瘤病相关听神经瘤治疗进展

Recent advance on the treatment of neurofibromatosis type 2-associated vestibular schwannoma

RichHTML

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	薛蓉, 张轩. 睡眠障碍对脑血管病的影响[J]. 中国现代神经疾病杂志, 2023, 23(8): 659-662.
[2]	张鹏, 陈涛, 许莉. 成人失眠认知行为疗法关键技术与流程改进建议[J]. 中国现代神经疾病杂志, 2023, 23(8): 663-667.
[3]	张轩, 薛蓉. 特发性快速眼动睡眠期行为障碍向神经系统变性疾病转化的生物学标志物研究进展[J]. 中国现代神经疾病杂志, 2023, 23(8): 668-673.
[4]	刘引, 汤永红, 翟锦霞, 邱媛. 慢性低度炎症与睡眠障碍研究进展[J]. 中国现代神经疾病杂志, 2023, 23(8): 674-677.
[5]	于洁洋, 张亚男, 李惠敏, 黄真灿, 李宛儒, 王赞. 发作性睡病与焦虑研究进展[J]. 中国现代神经疾病杂志, 2023, 23(8): 678-682.
[6]	库成心, 邓丽影, 谢亮. 缺血性卒中继发日间过度思睡研究进展[J]. 中国现代神经疾病杂志, 2023, 23(8): 683-686.
[7]	姜佳凤, 赵莲花, 赵伟. 褪黑素在阿尔茨海默病病理损害机制中的作用[J]. 中国现代神经疾病杂志, 2023, 23(8): 687-692.
[8]	黄沛, 王刚. 功能性帕金森综合征诊断与治疗[J]. 中国现代神经疾病杂志, 2023, 23(8): 738-741.
[9]	洪涛, 唐斌. 如何成为一名优秀的颅底外科医师[J]. 中国现代神经疾病杂志, 2023, 23(7): 571-574.
[10]	张庆硕, 宋丹丹, 周世越, 张金璐, 韩晓旭, 许顺良. 功能性步态障碍诊断与治疗[J]. 中国现代神经疾病杂志, 2023, 23(7): 604-609.
[11]	潘希娟, 邢英琦, 刘玉梅. 脑小血管病影像学评分方法[J]. 中国现代神经疾病杂志, 2023, 23(7): 633-637.
[12]	俞淑凤, 李宁, 徐健, 王鹏. 颈动脉漂浮血栓相关缺血性卒中诊断与治疗进展[J]. 中国现代神经疾病杂志, 2023, 23(7): 638-642.
[13]	魏俊吉. 神经外科重症医学规范化诊断与治疗[J]. 中国现代神经疾病杂志, 2023, 23(6): 477-478.
[14]	杜倩, 邓素君, 邹姗, 金珺, 周青山. 宏基因组第二代测序技术在重症中枢神经系统感染中的应用[J]. 中国现代神经疾病杂志, 2023, 23(6): 479-484.
[15]	曲鑫, 赵浩, 尚峰, 王宁. 神经重症目标温度管理[J]. 中国现代神经疾病杂志, 2023, 23(6): 485-489.

模态框（Modal）标题

选择文件类型/文献管理软件名称

选择包含的内容

2 Ⅱ型神经纤维瘤病相关听神经瘤治疗进展

Recent advance on the treatment of neurofibromatosis type 2-associated vestibular schwannoma

RichHTML

PDF

可视化

被引次数

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价